ClinicalTrials.gg
CompletedNCT00744627Updated Mar 3, 2014Results posted

Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.

A Phase 3 interventional study of Vortioxetine and Placebo in Generalized Anxiety Disorder, sponsored by Takeda. Completed at 38 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-03.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Generalized Anxiety Disorder with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Generalized Anxiety Disorder · Russian Federation.

Enrollment
8th of 10
301 · median 405
Started
2008
with 3 others
Phase 3
7 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Takeda

Among the 10 studies in Generalized Anxiety Disorder with a site in Russian Federation, this one is the 8th largest by enrollment, is one of 4 that started in 2008, is one of 7 in phase 3, and was the 7th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

None of the 10 studies in Generalized Anxiety Disorder with a site in Russian Federation is open now. The open studies under Generalized Anxiety Disorder, anywhere →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Generalized Anxiety Disorder with a site in Russian Federation as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of vortioxetine, once daily (QD), in adults with Generalized Anxiety Disorders.

Read the detailed description

The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested to treat anxiety in adults who have general anxiety disorder (GAD). This study looked at GAD relief in people who took vortioxetine.

The study enrolled 301 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):

  • Vortioxetine 5 mg
  • Placebo (dummy inactive pill) - this was a capsule that looked like the study drug but had no active ingredient.

All participants were asked to take one capsule at the same time each day throughout the study.

This multi-center trial was conducted in Europe. The overall time to participate in this study was up to 13 weeks. Participants made 7 visits to the clinic, and were contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • Generalized Anxiety Disorder
  • Anxiety Disorders
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suffers from a primary diagnosis of Generalized Anxiety Disorder according to , Fourth Edition, Text Revision (DSM-IV-TR) criteria.
  • Has a Hamilton Anxiety Scale total score ≥20 at Screening and Baseline.
  • Has a Hamilton Anxiety Scale score ≥2 on both Item 1 (anxious mood) and Item 2 (tension) at Screening and Baseline.
  • Has a Montgomery-Åsberg Depression Rating Scale total score ≤16 at Screening and Baseline.
  • Male and females of who are sexually active agree to use adequate from Screening throughout the duration of the study and for 1 month after the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  • Has received any compound \<30 days before Screening or 5 half-lives prior to Screening.
  • Has received Lu AA21004 in a previous clinical study or as a therapeutic agent.
  • Has 1 or more of the following:

    • Any current psychiatric disorder other than Generalized Anxiety Disorder as defined in the .
    • Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR.
    • Presence or history of a neurological disorder (including epilepsy).
    • Neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington disease, etc).
    • Any Axis II disorder that might compromise the study.
  • Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study including:

    • Nonsteroidal anti-inflammatory drugs
    • Rifampin
    • Macrolide antibiotics
    • Hormones
    • Hypoglycemic agents and Insulin
    • Systemic
    • Antineoplastics
    • Antiobesity agents
    • Antidiarrheal agents (episodic use allowed)
    • Antifungal agents (episodic topical use allowed)
    • Antihistamines (episodic use of loratadine, desloratadine, cetirizine allowed)
    • Cough/cold agents (episodic use allowed but preparations containing pseudoephedrine and narcotics are NOT allowed)
    • Diuretics (episodic use allowed)
  • Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on item 10 (suicidal thoughts) of the Montgomery-Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.
  • Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
  • Has received electroconvulsive therapy within 6 months prior to Screening.
  • Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
  • Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.
  • Has an , aspartate aminotransferase or level >1.5 times the .
  • Has a serum creatinine of >1.5 times the upper limits of normal.
  • Has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication. This criterion does not include those participants with basal cell or stage I squamous cell carcinoma of the skin.
  • Has clinically significant abnormal vital signs as determined by the investigator.
  • Has 1 or more laboratory values outside the normal range, based on the blood or urine samples taken at Screening, that are considered by the investigator to be clinically significant.
  • Has thyroid stimulating hormone value outside the normal range at Screening and is deemed clinically significant by the investigator.
  • Has an abnormal as determined by the central reader and confirmed as clinically significant by the investigator.
  • Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
  • Has previously participated in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
301 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.

    Drug: Placebo

  • Experimental
    Vortioxetine 5 mg

    Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.

    Drug: Vortioxetine

Interventions

  • Encapsulated vortioxetine immediate-release tablets.

    Also known as: Lu AA21004, Brintellix®

  • DrugPlacebo

    Vortioxetine placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8

    The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Week 8

  2. Clinical Global Impression Scale-Global Improvement at Week 8

    The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a MMRM with baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Week 8

  3. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Week 8

  4. Percentage of Responders in HAM-A Total Score at Week 8

    Response was defined as participants with a ≥ 50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

    Time frame: Baseline and Week 8

  5. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Week 8

  6. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Week 8

  7. Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 1, 2, 4 and 6.

  8. Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed

    The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 1 and 4

  9. Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed

    The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 1, 2, 4 and 6

  10. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 1, 2 and 4

  11. Percentage of Responders in HAM-A Total Score at Other Weeks Assessed

    Response was defined as participants with a ≥ 50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

    Time frame: Baseline and Weeks 1, 2, 4 and 6

  12. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 1, 2, 4 and 6

  13. Percentage of Participants in HAM-A Remission at Each Week Assessed

    Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

    Time frame: Weeks 1, 2, 4, 6 and 8

  14. Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed

    The Clinical Global Impression-Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 1, 2, 4, 6 and 8

  15. Change From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed

    The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 1, 4 and 8

  16. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 2 and 4

  17. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The physical functioning subscale assesses limitations in physical activities because of health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 2, 4 and 8

  18. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-physical subscale assesses limitations in usual role activities because of physical health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 2, 4 and 8

  19. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The bodily pain sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 2, 4 and 8

  20. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The general health sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 2, 4 and 8

  21. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 2, 4 and 8

  22. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 2, 4 and 8

  23. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The mental health sub-score assesses general mental health (psychological distress and well-being) and ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

    Time frame: Baseline to Weeks 2, 4 and 8

  24. Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire

    Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

    Time frame: Baseline and Week 8

07

Results

Posted Mar 3, 2014

Participant flow

Participants took part in the study at 47 investigative sites in Europe from 23 September 2008 to 07 July 2009.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 5 mg
Started151150
Treated150150
Completed126128
Not completed2522
Withdrew: Adverse event69
Withdrew: Lack of efficacy73
Withdrew: Noncompliance01
Withdrew: Protocol deviations02
Withdrew: Voluntary withdrawal96
Withdrew: Lost to follow-up21
Withdrew: Other10

Outcome measures

PrimaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8
scores on a scalePlaceboVortioxetine 5 mg
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8-10.49 ± 0.697-14.30 ± 0.695
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = <0.001 (Pre-specified sequential statistical testing procedure indicates that when p-value \<0.05, hierarchical testing continues.) · Ls mean difference: -3.81 · 95% CI -5.74 to -1.88P-values were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
SecondaryChange From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8

The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8
scores on a scalePlaceboVortioxetine 5 mg
Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8-4.20 ± 0.396-6.49 ± 0.393
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = <0.001 (Pre-specified sequential statistical testing procedure indicates that when p-value \<0.05, hierarchical testing continues.) · Ls mean difference: -2.30 · 95% CI -3.39 to -1.20P-values were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis
SecondaryClinical Global Impression Scale-Global Improvement at Week 8

The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a MMRM with baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression Scale-Global Improvement at Week 8
scores on a scalePlaceboVortioxetine 5 mg
Clinical Global Impression Scale-Global Improvement at Week 82.66 ± 0.0982.19 ± 0.098
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = <0.001 (Pre-specified sequential statistical testing procedure indicates that when p-value \<0.05, hierarchical testing continues.) · Ls mean difference: -0.46 · 95% CI -0.73 to -0.19P-values were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
scores on a scalePlaceboVortioxetine 5 mg
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8-6.14 ± 0.631-8.10 ± 0.656
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.031 (Pre-specified sequential statistical testing procedure indicates that when p-value \<0.05, hierarchical testing continues.) · Ls mean difference: -1.96 · 95% CI -3.74 to -0.18P-values were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
SecondaryPercentage of Responders in HAM-A Total Score at Week 8

Response was defined as participants with a ≥ 50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Percentage of Responders in HAM-A Total Score at Week 8
percentage of participantsPlaceboVortioxetine 5 mg
Percentage of Responders in HAM-A Total Score at Week 839.961.7
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Regression, Logistic · p = <0.001 (Pre-specified sequential statistical testing procedure indicates that when p-value \<0.05, hierarchical testing continues.) · Odds ratio (or): 2.393 · 95% CI 1.496 to 3.830Logistic regression with explanatory variables for treatment and Baseline HAM-A score.
SecondaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25
scores on a scalePlaceboVortioxetine 5 mg
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25-10.44 ± 0.895-15.55 ± 0.904
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = <0.001 (Pre-specified sequential statistical testing procedure indicates that when p-value \<0.05, hierarchical testing continues.) · Ls mean difference: -5.10 · 95% CI -7.61 to -2.60P-values were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8
scores on a scalePlaceboVortioxetine 5 mg
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 818.02 ± 1.99126.80 ± 1.974
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.002 (SF-36 social functioning subscore was the last endpoint to be tested in the hierarchical testing sequence.) · Ls mean difference: 8.78 · 95% CI 3.32 to 14.25P-values were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
SecondaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 1, 2, 4 and 6.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=146, 148)-2.46 ± 0.272-2.50 ± 0.270
Week 2 (n=147, 144)-5.05 ± 0.407-6.21 ± 0.408
Week 4 (n=136, 137)-7.43 ± 0.539-9.62 ± 0.538
Week 6 (n=128, 129)-9.17 ± 0.609-11.93 ± 0.608
SecondaryChange From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed

The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 1 and 4
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=146, 148)-1.42 ± 0.226-1.14 ± 0.223
Week 4 (n=140, 140)-3.13 ± 0.298-4.07 ± 0.296
SecondaryClinical Global Impression Scale-Global Improvement at Other Weeks Assessed

The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=146, 148)3.58 ± 0.0533.67 ± 0.053
Week 2 (n=147, 144)3.31 ± 0.0703.10 ± 0.070
Week 4 (n=136, 137)2.99 ± 0.0802.66 ± 0.080
Week 6 (n=128, 129)2.74 ± 0.0862.43 ± 0.086
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 1, 2 and 4
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=121, 117)-1.32 ± 0.314-1.12 ± 0.329
Week 2 (n=122, 114)-2.93 ± 0.440-3.04 ± 0.459
Week 4 (n=112, 107)-4.35 ± 0.546-5.13 ± 0.566
SecondaryPercentage of Responders in HAM-A Total Score at Other Weeks Assessed

Response was defined as participants with a ≥ 50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

Time frame:
Baseline and Weeks 1, 2, 4 and 6
Reported as:
Number · percentage of participants
Percentage of Responders in HAM-A Total Score at Other Weeks Assessed
percentage of participantsPlaceboVortioxetine 5 mg
Week 1 (n=146, 148)2.72.0
Week 2 (n=148, 149)12.212.1
Week 4 (n=148, 149)20.328.9
Week 6 (n=148, 149)29.743.6
SecondaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=100, 95)-2.64 ± 0.332-2.62 ± 0.341
Week 2 (n=99, 92)-4.89 ± 0.507-6.43 ± 0.522
Week 4 (n=89, 89)-7.33 ± 0.694-10.08 ± 0.702
Week 6 (n=83, 83)-9.02 ± 0.763-12.90 ± 0.771
SecondaryPercentage of Participants in HAM-A Remission at Each Week Assessed

Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

Time frame:
Weeks 1, 2, 4, 6 and 8
Reported as:
Number · percentage of participants
Percentage of Participants in HAM-A Remission at Each Week Assessed
percentage of participantsPlaceboVortioxetine 5 mg
Week 1 (n=146, 148)00
Week 2 (n=148, 149)2.72.7
Week 4 (n=148, 149)6.88.7
Week 6 (n=148, 149)12.216.8
Week 8 (n=148, 149)17.630.2
SecondaryChange From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed

The Clinical Global Impression-Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 1, 2, 4, 6 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=146, 148)-0.23 ± 0.039-0.19 ± 0.039
Week 2 (n=147, 144)-0.53 ± 0.060-0.60 ± 0.060
Week 4 (n=136, 137)-0.87 ± 0.071-1.04 ± 0.071
Week 6 (n=128, 129)-1.09 ± 0.080-1.40 ± 0.080
Week 8 (n=126, 128)-1.26 ± 0.096-1.78 ± 0.095
SecondaryChange From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed

The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 1, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=146, 148)-0.18 ± 0.178-0.28 ± 0.176
Week 4 (n=140, 140)-1.08 ± 0.245-1.62 ± 0.245
Week 8 (n=128, 129)-1.50 ± 0.297-3.18 ± 0.295
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 2 and 4
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=147, 149)8.50 ± 1.5368.83 ± 1.519
Week 4 (n=136, 137)11.41 ± 1.77318.45 ± 1.758
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The physical functioning subscale assesses limitations in physical activities because of health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=147, 149)2.54 ± 1.1603.39 ± 1.146
Week 4 (n=136, 137)2.15 ± 1.1498.34 ± 1.137
Week 8 (n=128, 129)4.48 ± 1.27110.69 ± 1.258
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-physical subscale assesses limitations in usual role activities because of physical health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=147, 149)4.72 ± 1.4885.99 ± 1.474
Week 4 (n=136, 137)6.89 ± 1.59211.89 ± 1.578
Week 8 (n=128, 129)8.96 ± 1.89718.39 ± 1.880
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The bodily pain sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=147, 149)6.49 ± 1.7027.40 ± 1.681
Week 4 (n=136, 137)6.81 ± 1.87510.62 ± 1.856
Week 8 (n=128, 129)10.90 ± 1.90315.38 ± 1.883
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The general health sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=147, 149)4.54 ± 0.9926.04 ± 0.979
Week 4 (n=136, 137)8.45 ± 1.29210.36 ± 1.280
Week 8 (n=128, 129)9.76 ± 1.40916.30 ± 1.396
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=147, 149)5.44 ± 1.2758.11 ± 1.261
Week 4 (n=136, 137)8.36 ± 1.50013.38 ± 1.486
Week 8 (n= 128, 129)12.56 ± 1.68622.53 ± 1.671
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=147, 149)7.27 ± 1.4809.62 ± 1.463
Week 4 (n=136, 137)13.41 ± 1.87119.04 ± 1.856
Week 8 (n=128, 129)18.96 ± 2.13828.13 ± 2.121
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The mental health sub-score assesses general mental health (psychological distress and well-being) and ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=147, 149)5.58 ± 1.1668.90 ± 1.152
Week 4 (n=136, 137)9.79 ± 1.43214.73 ± 1.421
Week 8 (n=128, 129)13.51 ± 1.69321.75 ± 1.681
SecondaryHealth Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire

Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
participantsPlaceboVortioxetine 5 mg
Baseline: Any resource use7984
Baseline: Any hospitalization-related services73
Baseline: Hospitalization related to anxiety42
Baseline: Any sick leave77
Baseline: Sick leave related to anxiety44
Week 8: Any resource use1425
Week 8: Any hospitalization-related service01
Week 8: Hospitalization related to anxiety00
Week 8: Any sick leave24
Week 8: Sick leave related to anxiety23

Adverse events

Collected over Safety was assessed during the 8-week treatment period and a 4-week follow-up period.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/150 (0.7%)36/150 (24%)
Vortioxetine 5 mg—0/150 (0%)48/150 (32%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 5 mg
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1500/150
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboVortioxetine 5 mg
NauseaGastrointestinal disorders9/15018/150
HeadacheNervous system disorders13/15012/150
DizzinessNervous system disorders4/1509/150
SomnolenceNervous system disorders2/1506/150
Dry mouthGastrointestinal disorders4/1505/150
VomitingGastrointestinal disorders5/1502/150
NasopharyngitisInfections and infestations1/1505/150
HyperhidrosisSkin and subcutaneous tissue disorders1/1505/150
DiarrhoeaGastrointestinal disorders4/1503/150
FatigueGeneral disorders4/1501/150

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboVortioxetine 5 mgTotal
Mean45.3 ± 13.4945.0 ± 14.0745.1 ± 13.76
Age, Customized
Age, Customized(participants)PlaceboVortioxetine 5 mgTotal
≤55 years112111223
>55 years393978
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 5 mgTotal
Female93103196
Male5847105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 5 mgTotal
Caucasian (White, including Hispanic)151150301
Black000
Asian000
American Indian or Alaska Native000
Native Hawaiian/ Other Pacific Islander000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 5 mgTotal
Hispanic/Latino8513
Non-Hispanic/Non-Latino143145288
Region of Enrollment
Region of Enrollment(participants)PlaceboVortioxetine 5 mgTotal
Estonia7310
Germany343771
Latvia7512
Lithuania81119
Poland283159
Romania538
Russia484997
Ukraine141125
Weight
Weight(kg)PlaceboVortioxetine 5 mgTotal
Mean75.76 ± 16.37072.97 ± 14.98174.37 ± 15.729
Height
Height(cm)PlaceboVortioxetine 5 mgTotal
Mean169.56 ± 9.457168.21 ± 8.653168.89 ± 9.075

8 further baseline measures are reported on the registry.

08

Study locations

38 sites
  • Tallinn, Estonia
  • Viljandi, Estonia
  • Bad Saarow, Germany
  • Berlin, Germany
  • Bochum, Germany
  • Huettenberg, Germany
  • Rodgau, Germany
  • Schwerin, Germany
  • Wiesbaden, Germany
  • Liepaja, Latvia
  • Riga, Latvia
  • Sigulda, Latvia
  • Kaunas, Lithuania
  • Palanga, Lithuania
  • Vilnius, Lithuania
  • Białystok, Poland
  • Gdynia, Poland
  • Gorlice, Poland
  • Leszno, Poland
  • Skórzewo, Poland
  • Toruń, Poland
  • Tuszyn, Poland
  • Bucharest, Romania
  • Oradea, Romania
  • Ekaterinburg, Russian Federation
  • Kazan, Russian Federation
  • Lipetsk, Russian Federation
  • Moscow, Russian Federation
  • Rostov-on-Don, Russian Federation
  • Samara, Russian Federation
  • Smolensk, Russian Federation
  • St. Petersburg, Russian Federation
  • Stavropol, Russian Federation
  • Dnepropetrovsk, Ukraine
  • Kharkiv, Ukraine
  • Liev, Ukraine
  • Lugansk, Ukraine
  • Simferopol, Ukraine
09

References and documents

Publications

  • Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012 Dec;22(12):847-57. doi: 10.1016/j.euroneuro.2012.07.012. Epub 2012 Aug 14. PubMed 22898365 ↗
  • Christensen MC, Loft H, Florea I, McIntyre RS. Efficacy of vortioxetine in working patients with generalized anxiety disorder. CNS Spectr. 2019 Apr;24(2):249-257. doi: 10.1017/S1092852917000761. Epub 2017 Oct 30. Erratum In: CNS Spectr. 2019 Apr;24(2):275. doi: 10.1017/S1092852918000974. PubMed 29081307 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2008
First posted
Sep 1, 2008
Start
Sep 2008
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Mar 3, 2014
Last update
Mar 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00744627
Lead sponsor
Takeda
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Sep 1, 2008
Start date
Sep 2008
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Mar 3, 2014
Last update
Mar 3, 2014

Study contacts

Medical Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion